Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487582 | 0.91 | GPR119 (0.66) | GPR119 | |
| SCHEMBL11885632 | 0.91 | GPR119 (0.66) | GPR119 | |
| SCHEMBL14874940 | 0.86 | GPR119 (0.57) | GPR119 | |
| SCHEMBL1118035 | 0.82 | GPR119 (0.78) | GPR119 | |
| SCHEMBL8024812 | 0.82 | GPR119 (0.54) | GPR119KCNH2 | |
| SCHEMBL1118394 | 0.82 | GPR119 (0.54) | GPR119KCNH2 | |
| SCHEMBL8023326 | 0.82 | GPR119 (0.55) | GPR119KCNH2 | |
| SCHEMBL1118305 | 0.82 | GPR119 (0.65) | GPR119KCNH2 | |
| SCHEMBL8022934 | 0.82 | GPR119 (0.65) | GPR119KCNH2 | |
| SCHEMBL3488514 | 0.82 | GPR119 (0.55) | GPR119KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638541-B2 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638541-B2 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX, INC. (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | SLC5A2, IAPP, GPR119 | GPR119 3/4885KCNH2 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.